Investigational drug · Phase 3
SL1002
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Osteoarthritis Knee Pain.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "SL1002"
First trial start
2025
Nov 7, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SL1002", any sponsor or status.
Conditions studied
As listed on its trial records.
- Osteoarthritis Knee Pain
Approved drugs for the same conditions: Osteoarthritis · Pain and anesthesia
Largest trials
Live from ClinicalTrials.gov: studies naming "SL1002" as an intervention, largest first.
- Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee PainPivotal-lookingActive, not recruiting
Saol Therapeutics IncIndustry
NCT07226258 · 150 participants (planned) · Start Nov 7, 2025 · Primary completion Nov 30, 2026
Drug: SL1002; Normal Saline · For: Osteoarthritis Knee Pain
Sites: Roseville, California; San Diego, California; Greenwood Village, Colorado · 22 sites in all
- Phase II Study to Assess Safety and Efficacy of SL-1002 for Osteoarthritic Knee PainPivotal-lookingStatus unknown
Saol Therapeutics IncIndustry
NCT05470608 · 132 participants (planned) · Start Jun 13, 2022 · Primary completion Jan 2024
Drug: SL-1002; Placebo · For: Osteoarthritis, Knee Pain
Sites: Greenwood Village, Colorado; Washington D.C., District of Columbia; Coral Gables, Florida · 15 sites in all
- Phase II Study to Assess Safety, Pharmacokinetics and Efficacy of SL-1002 for Limb SpasticityStatus unknown
Saol Therapeutics IncIndustry
NCT05311215 · 32 participants (planned) · Start Apr 22, 2022 · Primary completion Sep 2023
Drug: SL-1002; Placebo · For: Spasticity
Sites: Houston, Texas; Milwaukee, Wisconsin
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.